Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
- 31 August 2012
- journal article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 13 (8), 810-816
- https://doi.org/10.1016/s1470-2045(12)70294-2
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activityAnnals Of Oncology, 2011
- (Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis InhibitorThe Oncologist, 2010
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitorsBritish Journal of Cancer, 2009
- Phase 2 trial of sorafenib in patients with advanced urothelial cancerCancer, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- Evaluation of hypoxia‐inducible factor 1α overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinomaBJU International, 2005
- Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendationsEuropean Journal Of Cancer, 1999
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989